, Azadeh Hajmirza has been the recipient of doctoral funding from the Société Française d'Hématologie. Additional support was from Jannsen-Cilag and Mundipharma
Molecular pathogenesis of mantle cell lymphoma, The Journal of clinical investigation, vol.122, 2012. ,
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02331700
Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling, Blood, vol.116, p.953, 2010. ,
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, p.3161, 2013. ,
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma, Blood, vol.119, 1963. ,
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, p.2988, 2014. ,
Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma, Nature medicine, vol.20, 2014. ,
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences of the United States of America, vol.110, p.18250, 2013. ,
Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms, Blood, vol.127, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01920364
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, p.2375, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype, Leukemia, vol.29, p.1177, 2015. ,
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer discovery, vol.4, p.1022, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02490276
The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science, vol.355, p.1147, 2017. ,
Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis, Oncogene, vol.28, p.1053, 2009. ,
Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia, Blood, vol.126, p.195, 2015. ,
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet. Oncology, vol.16, p.1111, 2015. ,
,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011. ,
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-2390, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes, Semin. Cancer Biol, vol.21, pp.293-298, 2011. ,
, Lymphome à cellules du manteau, p.10, 2017.
Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases, J. Cutan. Pathol, vol.43, pp.1112-1120, 2016. ,
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior, Haematologica, vol.97, pp.270-278, 2012. ,
A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature, Case Rep. Hematol, p.145129, 2014. ,
Multifocal mantle cell lymphoma in situ in the setting of a composite lymphoma, Am. J. Clin. Pathol, vol.143, p.307, 2015. ,
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network, Br. J. Haematol, vol.131, pp.29-38, 2005. ,
The cellular origin of mantle cell lymphoma, Int. J. Biochem. Cell Biol, vol.39, pp.1747-1753, 2007. ,
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics, Nat. Rev. Cancer, vol.7, pp.750-762, 2007. ,
CD5-mantle cell lymphoma, Am. J. Clin. Pathol, vol.118, pp.216-224, 2002. ,
Molecular diagnosis of t(11;14) in mantle cell lymphoma using two-colour interphase fluorescence in situ hybridization, Br. J. Haematol, vol.93, pp.656-660, 1996. ,
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma, Blood, vol.121, pp.1394-1402, 2013. ,
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, pp.2257-2317, 2003. ,
Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma, Leuk. Res, vol.31, pp.1219-1230, 2007. ,
Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling, Blood, vol.116, pp.953-961, 2010. ,
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est, Etude des Leucémies et Autres Maladies du Sang ,
, Br. J. Haematol, vol.158, pp.186-197, 2012.
, Rev. Med. Liege, vol.65, pp.171-176, 2010.
SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma, Biomark. Res, vol.4, p.6, 2016. ,
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype, Haematologica, vol.94, pp.1555-1562, 2009. ,
The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes, Haematologica, vol.100, pp.369-372, 2015. ,
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling, Blood, vol.106, pp.4315-4321, 2005. ,
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc. Natl. Acad. Sci. U. S. A, vol.110, pp.18250-18255, 2013. ,
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, pp.3161-3164, 2013. ,
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma, Blood, vol.119, pp.1963-1971, 2012. ,
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, pp.2988-2996, 2014. ,
Pharmacological and genomic profiling identifies NF-?B-targeted treatment strategies for mantle cell lymphoma, Nat. Med, vol.20, pp.87-92, 2014. ,
A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL), Blood, vol.126, pp.336-336, 2015. ,
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage, Cancer Cell, vol.30, pp.806-821, 2016. ,
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, pp.558-565, 2008. ,
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.32, pp.1338-1346, 2014. ,
Outcome of deferred initial therapy in mantle-cell lymphoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.1209-1213, 2009. ,
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management, Am. J. Hematol, vol.92, pp.806-813, 2017. ,
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma, N. Engl. J. Med, vol.377, pp.1250-1260, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02329536
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N. Engl. J. Med, vol.369, pp.507-516, 2013. ,
Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma, Am. Health Drug Benefits, vol.8, pp.135-140, 2015. ,
Cell-cycle reprogramming for PI3K inhibition overrides a relapsespecific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, pp.1022-1035, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02490276
BET Family Protein BRD4: An Emerging Actor in NF?B Signaling in Inflammation and Cancer, Biomedicines, vol.6, 2018. ,
The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science, vol.355, pp.1147-1152, 2017. ,
Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis, Oncogene, vol.28, pp.1053-1062, 2009. ,
Role of novel histone modifications in cancer, Oncotarget, vol.9, pp.11414-11426, 2017. ,
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, Lancet Oncol, vol.16, pp.1111-1122, 2015. ,